Business Wire

Huawei Launch Track AI to Help Detect Early Signs of Visual Impairment in Children across the World

Del

Huawei has deployed its AI expertise with leading medical research bodies to help safeguard children's eyesight. Huawei is working with IIS Aragon and DIVE Medical to co-create Track AI, an AI-powered assessment designed to detect and diagnose early signs of visual impairment in children.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190415005748/en/

The World Health Organization estimates there are 19 million children in the world with visual impairment, of which 70 to 80 percent are preventable or curable. In most cases, these children will remain undiagnosed for years, resulting in more serious consequences with their vision, general development, educational and social opportunities. Less severe but easily prevented types of visual impairments are currently affecting 12.8 million children.

For the past few years, we have been committed to developing a tool that will assess visual function in young children and to identify those with visual impairments,” said Victoria Pueyo, Paediatric Ophthalmologist, DIVE Medical.

“With Huawei supporting and powering DIVE through AI we are now able to work towards this goal. Our goal is to implement this technology globally and with our multi-ethnic approach we can cater to every type of visual impairment.”

To detect visual impairments, the DIVE (Devices for an Integral Visual Examination) software runs on the Matebook E to monitor and track the gaze of each eye while the patient is looking at stimuli designed to test different aspects of visual function. The data collected from the patients’ gaze pattern is then processed on the HUAWEI P30 smartphone using the HUAWEI HiAI algorithm to identify potential indicators of visual impairments.

With the HUAWEI P30 and HUAWEI HiAI technology, the Track AI initiative creates an easy-to-use, portable and affordable device to identify these issues in children as soon as possible and as early as six months old. Ultimately, the goal is to empower individuals without training to help identify children that may have visual impairments in order to help them access treatment sooner.

In the past, smartphones were not powerful enough to process complex AI based algorithms and data had to be sent to the cloud for processing. Communication to and from the cloud makes AI processing slow and is useless without a network. The new Track AI technology combines the very best in Huawei’s machine learning and on-device AI processing technology with concrete research and insights from IIS Aragon and DIVE Medical, said Peter Gauden, Technology Expert, Huawei.

Track AI is part of Huawei’s wider commitment to push the boundaries of what is humanly possible and use AI for good. Our goal for this project is to make it possible for parents and doctors in all corners of the world to detect visual impairments in a faster, easier, more efficient way through AI technology.”

How does it work?

Children with visual impairment have different gaze patterns compared to children with normal vision. DIVE can accurately gather data on the gaze position during a scientifically designed visual stimuli. Interpreting this data can be challenging for non-specialist healthcare workers. Using AI, however, computers can be trained to identify abnormal gaze patterns for easier screenings and assisted diagnoses and speed up the process from diagnosis to management of the condition.

Track AI builds on the capabilities of Google’s TensorFlow, an open-source platform, and Huawei HiAi, to create a machine learning system on a smartphone using its breakthrough Kirin 980 chip, an AI processing powerhouse that is defining the future of smartphone AI.

Two dedicated Neural Processing Units (Dual NPU) built inside the Kirin 980 support on-device AI which means the AI functions are processed on the smartphone itself, significantly speeding things up while also preserving user privacy. This Dual Neural Processing Unit also helps to make the Smartphone's AI features smarter over time as well as increase daily performance and efficiency.

Track AI on the smartphone is portable, doesn’t require WI-FI and receives data in real-time to speed diagnoses. The unprecedented capabilities of Huawei’s smartphone allow Track AI to be used across the world, from an ophthalmologist in a UK hospital to a village doctor in a remote area of Africa.

Early trials will soon lead to widespread adoption. Developing a system based on AI requires gathering data from thousands of children, and data is currently being collecting by the research centres from testing in five countries across 3 continents (China, Mexico, UAE, Spain and UK). Once a mass of data has been aggregated, neural networks will be trained and a prototype device will be piloted later this year with plans to roll-out in 2020, helping healthcare workers diagnose and treat eye conditions early.

The new HUAWEI P30 an HUAWEI P30 Pro are immediately available globally with pricing information as follows:

HUAWEI P30 Pro

  • 8GB RAM + 128GB ROM - EUR 999
  • 8GB RAM + 256GB ROM - EUR 1,099
  • 8GB RAM + 512GB ROM - EUR 1,249

HUAWEI P30

  • 6GB RAM + 128GB ROM - EUR 799

-ends-

Contact information

H+K Strategies
Kandance Williamson
HuaweiP30@hkstrategies.com
Tel: +44 (0) 207 413 3000

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Forter Readies Merchants with Launch of PSD2-Compliant Solution25.4.2019 11:25:00 CESTPressemelding

Forter, the leading e-commerce fraud prevention company, today launches its PSD2-compliant merchant offering, Forter PSD2 Solution for Merchants . The comprehensive, payment processor-agnostic solution enables merchants to dynamically route customers to the path of least friction required, prevent all types of fraud and violations of business policies, and optimise the customer’s payment experience – all while meeting full PSD2 compliance. As of 14 September 2019, the revised Payment Services Directive (PSD2) introduces the requirement for merchants to authenticate online transactions within the European Economic Area using Strong Customer Authentication (SCA). Under SCA, merchants have to introduce additional friction into the purchasing process for customers, which will lead to increased drop-off rates, reduce overall conversion rates, and provide a poor customer experience. These changes could ultimately hurt revenue, so merchants must mitigate these challenges and minimise the impa

The Smarter E Europe – Explore Sector Coupling for Yourself at Europe’s Largest Platform for the Energy Industry25.4.2019 09:53:00 CESTPressemelding

The innovation hub The smarter E Europe, encompassing the exhibitions Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power, was launched in 2018 and has seen impressive growth ever since. It will be held for the second time from May 15–17, 2019 at Messe München and will now cover 10 exhibition halls, making it Europe’s largest energy industry event. This growth is due in large part to the upward trend in renewable energies. Since 2010, the proportion of energy generated worldwide from renewable sources has risen from 20 to 25 percent. By 2030, we’re looking at a jump to around 60 percent. In Germany, an average of 45 percent of all electricity generated already came from renewables in the first quarter of 2019. This dynamism is stimulating innovation and shaping the modern energy industry. The buzzword of the hour is sector coupling – a unification of the previously independent electricity, heating and transportation sectors. For instance, a photovoltaic (PV) installation in

The “One and Done” Era for Orphan Drugs: Evaluate Predicts 12% Growth, Driven by New Technologies, but Benefits Go to Big Pharma25.4.2019 07:00:00 CESTPressemelding

Scientific advancements will help propel the orphan drug market to a 12% CAGR to 2024, double the 6% rate expected for non-orphan products. In addition to recent breakthrough cell and gene therapy products like Yescarta and Luxturna, a number of “one and done” treatments for orphan diseases are approaching the market, including Novartis’s Zolgensma and bluebird bio’s Lentiglobin. The explosion of new technologies brings their high price points into greater focus — for example, the $425,000 per eye list price for Spark’s Luxturna is the value-based price agreed on with Spark and payers. In 2018, the mean cost for an orphan drug was 4.5 times that of a non-orphan product. Despite the clear advancements in treatment, however, those calling for reform of the Orphan Drug Act may gain further ammunition. Big pharma continues to entrench their position in the orphan market, as evidenced by Bristol-Myers Squibb’s bid for Celgene, Roche’s pending acquisition of Spark, and Novartis’s $8.7bn paym

NTT Group Increases Capital in NTT Global Data Centers Corp. to Further Strengthen Data Center Business25.4.2019 06:00:00 CESTPressemelding

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), NTT Urban Development Corporation, Nippon Telegraph and Telephone Corporation (NTT Corporation), NTT Finance Corporation announced today that it has increased its capital in NTT Global Data Centers Corporation (NTT GDC), a subsidiary company handling centralized global construction, management and equipment wholesales for NTT group data centers. NTT GDC is capitalized at 1.25 billion JPY, of which 60% will be had share by NTT Com. And three other NTT Group companies newly acquired shares in NTT GDC, namely, NTT Urban Development Corporation (20%), NTT Corporation (10%) and NTT Finance Corporation (10%), all as of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006195/en/ NTT GDC oversees investment and asset-ownership functions for data center construction. Established last year

China Yiwu Imported Commodities Fair 2019 to Open in May25.4.2019 05:49:00 CESTPressemelding

China Yiwu Imported Commodities Fair 2019, the professional platform for international small commodities to enter China, will open on May 23-26, 2019 at the Yiwu International Expo Center in China’s small commodities paradise Yiwu City. The Fair of this year will cover an exhibition area of over 50,000 square meters, providing 2,000 international standard booths in 4 exhibition zones, namely Asia Pavilion I, Asia Pavilion II, European Pavilion and America-Australia-Africa & Cross-border Trade Pavilion. The imported commodities to be displayed will include household items, maternal and child supplies, beauty and personal care, crafts, home appliances, food and beverage, health and nutrition, fashion accessories, creative toys, stationery, sports goods, clothing and accessories. The Fair is expected to attract over 1,500 business companies and organizations from over 100 countries and regions across the world. The number of visitors and buyers will exceed 120,000. The Import Commodities

Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC25.4.2019 01:00:00 CESTPressemelding

NEC Corporation (NEC; TSE: 6701) and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, today announced a US$50M series A strategic investment in BostonGene by NEC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006170/en/ BostonGene, a pioneer in the use of biomedical software for advanced patient analysis, has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno- and targeted therapies. BostonGene’s solution includes: Genome and transcriptome sequencing methods to create a patient’s molecular profile. Algorithms that estimate the immune fitness and cancer characteristics of a patient. A continuously updated expert-curated and Artificial Intelligence (AI)-driven database of cancer research and clinical information. Cloud-native software that delivers a patien